Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 6, 2024

________________________________________

GoodRx Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

________________________________________


Delaware	001-39549	47-5104396
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2701 Olympic Boulevard
Santa Monica, California		90404
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (855) 268-2822

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the

registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	GDRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act

of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders

On June 6, 2024, GoodRx Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders. Holders of the

Company’s Class A common stock were entitled to one vote per share held as of the close of business on April 8, 2024 (the

“Record Date”) and holders of the Company’s Class B common stock were entitled to ten votes per share held as of the

Record Date. A total of 79,472,296 shares of the Company’s Class A common stock and 278,619,320 shares of the

Company’s Class B common stock were present in person or represented by proxy at the meeting, representing

approximately 98.7% of the combined voting power of the Company’s Class A and Class B common stock as of the Record

Date. The following are the final voting results for the proposals considered and voted upon at the meeting, each of which

were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April

25, 2024.

Item 1 — Election of three Class I directors for a term of office expiring on the date of the Annual Meeting of Stockholders to

be held in 2027 and until their respective successors have been duly elected and qualified or until their respective earlier

death, resignation or removal.


	Votes FOR	Votes WITHHELD	Broker Non-Votes
Douglas Hirsch	2,818,730,487	9,200,943	37,734,066
Kelly J. Kennedy	2,827,444,912	486,518	37,734,066
Agnes Rey-Giraud	2,818,445,912	9,485,518	37,734,066

Item 2 — Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public

accounting firm for the fiscal year ending December 31, 2024.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
2,865,260,377	336,904	68,215	0

Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
2,823,670,920	4,151,594	108,916	37,734,066

Based on the foregoing votes, the Company’s stockholders (i) elected Douglas Hirsch, Kelly J. Kennedy and Agnes Rey-

Giraud as Class I directors; (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent

registered public accounting firm for the fiscal year ending December 31, 2024; and (iii) approved, on an advisory (non-

binding) basis, the compensation of the Company’s named executive officers.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report

to be signed on its behalf by the undersigned hereunto duly authorized.


			GOODRX HOLDINGS, INC.

Date:	June 7, 2024	By:	/s/ Karsten Voermann
			Name: Karsten Voermann Title: Chief Financial Officer

Document And Entity Information	Jun. 06, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jun. 06, 2024
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Emerging Growth Company	false
Entity File Number	001-39549
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-5104396
City Area Code	855
Local Phone Number	268-2822
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	GDRX
Security Exchange Name	NASDAQ
Amendment Flag	false
Entity Central Index Key	0001809519
Entity Address, Address Line One	2701 Olympic Boulevard
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90404